Skip to content
Nizatidine
Axid Ar (nizatidine) is a small molecule pharmaceutical. Nizatidine was first approved as Axid on 1988-04-12. It is used to treat duodenal ulcer, dyspepsia, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Axid ar (generic drugs available since 2002-07-05, discontinued: Axid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nizatidine
Tradename
Company
Number
Date
Products
AXID ARGSKN-020555 OTC1996-05-09
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nizatidineANDA2021-03-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
duodenal ulcerEFO_0004607D004381K26
dyspepsiaEFO_0008533D004415K30
gastroesophageal refluxEFO_0003948D005764K21
heartburn—D006356R12
helicobacter infectionsEFO_1000961D016481—
peptic esophagitisEFO_1001095D004942—
stomach ulcer—D013276K25
urticariaEFO_0005531D014581L50
zollinger-ellison syndrome—D015043E16.4
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BA: H2-receptor antagonists
— A02BA04: Nizatidine
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic nephropathiesD003928EFO_0000401———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNIZATIDINE
INNnizatidine
Description
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
Classification
Small molecule
Drug classH2-receptor antagonists (cimetidine type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
Identifiers
PDB—
CAS-ID76963-41-2
RxCUI42319
ChEMBL IDCHEMBL3183075
ChEBI ID7601
PubChem CID4513
DrugBankDB00585
UNII IDP41PML4GHR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,095 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
397 adverse events reported
View more details